ScreenerHero

NRIXNurix Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · nurixtx.com
26.72USD-3.85%Mkt Cap: 2.77B $P/E: —

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory condit…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap2.77B $
Enterprise Value2.42B $
Revenue (TTM)36.77M $
Gross Profit-304.17M $
Net Income (TTM)-264.46M $
Revenue/Share0.3670 USD
Last Price26.72 USD
Fiscal Year EndNov 2025
MR QuarterMay 2026
Employees317
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-18.80
PEG—
EV/EBITDA-6.86
EV/Revenue65.87
P/S76.36
P/B6.97
EPS (TTM)-3.37
EPS (Forward)-1.44
52W Range
8.19592% of range28.23
52W High28.23 USD
52W Low8.195 USD
Profitability
Gross Margin0.00%
Oper. Margin-1041.73%
EBITDA Margin0.00%
Profit Margin-314.90%
ROE-49.09%
ROA-38.43%
Growth
Revenue Growth-79.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-249.47M $
CapEx (TTM)14.00M $
FCF Margin-447.79%
FCF Yield-5.94%
Net Debt-385.39M $
Net Debt/EBITDA1.09
Balance Sheet
Debt/Equity0.10
Current Ratio6.34
Quick Ratio6.18
Book Value/Sh3.883 USD
Cash/Share4.274 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)33.50 USD
Upside (mean)+25.4%
Target Range25.00 USD – 45.00 USD
$25.00+25.4% to mean$45.00
# Analysts16
Ownership
Shares Out.103.78M
Float79.65M
Insiders1.08%
Institutions113.93%
Short Interest
Short Ratio15.2d
Short % Float17.88%
Short % Out.17.68%
Shares Short18.35M
Short (prev mo.)17.80M
Technical
SMA 5023.05 (+15.9%)
SMA 20018.15 (+47.2%)
Beta1.79
S&P 52W Chg18.16%
Avg Vol (30d)1.08M
Avg Vol (10d)1.05M
Technical Indicators
RSI (14)65.6
MACD1.3046
MACD Signal1.2117
MACD Hist.+0.0929
BB Upper28.29 USD
BB Middle25.16 USD
BB Lower22.04 USD
BB Width24.86%
ATR (14)1.059 USD
Vol Ratio (20d)1.44x